# Program of Angiotensin-Neprilysin Inhibition in Admitted Patients With Worsening Heart Failure (PREMIER)

Study · id `cardio:ct-nct05164653` · Cardiovascular Atlas · release `a25293eeae6350fb` (public)

> General information from published sources, not medical advice, and not reviewed by clinicians. Check the cited source before relying on anything here. Sponsors do not influence what this atlas says.

The atlas's own text and curation may be reused under Creative Commons Attribution-NonCommercial 4.0 International (CC BY-NC 4.0, https://creativecommons.org/licenses/by-nc/4.0/): credit the atlas, and do not use it commercially without a licence from the owner. See the atlas About page. Text quoted from a source stays under that source's own terms, given as the source's reuse\_basis. The atlas's reuse terms do not cover it. The downloads list each quotation with its source in third\_party\_quotations.

**Registry record.** Assembled by a program from [ClinicalTrials.gov record NCT05164653](<https://clinicaltrials.gov/study/NCT05164653>), retrieved 26 October 2026. No person wrote or checked this page.

Also called: NCT05164653

Browse, organ or system: Heart  
Browse, condition area: Heart failure  

## In plain language

A phase 4 trial registered on ClinicalTrials.gov. The registry status is unknown. It plans to enroll 400 participants.

## Technical summary

Registry record NCT05164653. Randomized; no masking; primary purpose treatment. Start 2021-12-27 (actual); primary completion 2024-02-08 (actual). Results not posted.

## Key facts

- Design: Interventional study; randomized; no masking; primary purpose treatment
- Phase: Phase 4
- Enrolled: 400 participants (planned count; ClinicalTrials.gov record NCT05164653, source copy `cardio:ctgov-nct05164653-2024-08-21`, retrieved 2026-10-26)
- Started: 2021-12-27 (actual) (ClinicalTrials.gov record NCT05164653, source copy `cardio:ctgov-nct05164653-2024-08-21`, retrieved 2026-10-26)
- Primary completion: 2024-02-08 (actual) (ClinicalTrials.gov record NCT05164653, source copy `cardio:ctgov-nct05164653-2024-08-21`, retrieved 2026-10-26)
- Completion: 2025-03 (anticipated) (ClinicalTrials.gov record NCT05164653, source copy `cardio:ctgov-nct05164653-2024-08-21`, retrieved 2026-10-26)
- Countries: Japan (ClinicalTrials.gov record NCT05164653, source copy `cardio:ctgov-nct05164653-2024-08-21`, retrieved 2026-10-26)
- Care setting: Not reported
- Registry status: "UNKNOWN" (U.S. National Library of Medicine (ClinicalTrials.gov), source copy `cardio:ctgov-nct05164653-2024-08-21`, retrieved 2026-10-26)

## The registry's words

- Brief title: Program of Angiotensin-Neprilysin Inhibition in Admitted Patients With Worsening Heart Failure (PREMIER)
- Condition: Heart Failure
- Intervention (Drug): Sacubitril Valsartan Sodium Hydrate
- Intervention (Drug): Standard treatment
- Lead sponsor: Saga University
- Lead sponsor class: OTHER

## Connected pages

- Registry condition terms include this condition: Heart failure (`cardio:heart-failure`)
- Registry lists this organization as the lead sponsor: Saga University (`cardio:org-saga-university`)

### Other papers using this trial's data

- Registry lists this paper as a derived reference; the paper's PubMed record names this trial's registry number and no other, PubMed types it as a trial report dated on or after the primary completion, neither its types nor its title mark it as a protocol, a design, an observational study or work outside the trial's own data, and PubMed shows no retraction or expression of concern: In-hospital initiation of angiotensin receptor-neprilysin inhibition in acute heart failure: the PREMIER trial (`cardio:pubmed-39215531`)
- Registry lists this paper as a derived reference; the paper's PubMed record names this trial's registry number and no other, PubMed types it as a trial report dated on or after the primary completion, neither its types nor its title mark it as a protocol, a design, an observational study or work outside the trial's own data, and PubMed shows no retraction or expression of concern: Uptitration of Sacubitril/Valsartan in Acute Heart Failure: Insight from the PREMIER Study (`cardio:pubmed-40389107`)
- Registry lists this paper as a derived reference; the paper's PubMed record names this trial's registry number and no other, PubMed types it as a trial report dated on or after the primary completion, neither its types nor its title mark it as a protocol, a design, an observational study or work outside the trial's own data, and PubMed shows no retraction or expression of concern: Impact of estimated total blood volume on NT-proBNP response to angiotensin receptor-neprilysin inhibition in acute heart failure: Insights from the PREMIER study (`cardio:pubmed-42542200`)

Courtesy of the U.S. National Library of Medicine.

## Provenance

Content hash: 36256b1c886fb8162bfde7eff85238c697ebca4402018d1daed74f685dfdc360
Last substantive edit: 2026-11-08
Evidence last checked: Not recorded
